Navigation Links
Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer 'promising'
Date:1/15/2014

An article published in the January issue of the International Journal of Radiation Oncology, Biology and Physics reports results of the Radiation Therapy Oncology Group (RTOG) phase II clinical trial of Bevacizumab (Avastin) in addition to cisplatin and pelvic radiation for locally advanced cervical cancer. The group reports that the addition of Bevacizumab to the existing standard of care was safe and showed promising overall results. The 2- and 3- year overall survival rates were 89.8 percent and 80.2 percent, respectively.

"Cervical cancer is a huge problem worldwide, but isn't as big a problem in the United States. So in many ways it tends to become a somewhat overlooked and under-studied disease," says Tracey Schefter, MD, investigator at the University of Colorado Cancer Center, director of the Stereotactic Body Radiation Therapy program at the University of Colorado School of Medicine, and the study's lead author.

Risk factors for cervical cancer include infection with the human papilloma virus (HPV). Screening dramatically reduces both the likelihood of developing cervical cancer and the disease's mortality rate. Combined, these two factors mean that 80 percent of the world's approximately 473,000 yearly cases of cervical cancer occur in the developing world. In the United States, cervical cancer rates have dropped 74 percent over the previous 50 years, but is still diagnosed in approximately 10,000 women per year, with 3,500 deaths due to the disease.

The current phase II clinical trial enrolled 49 eligible patients from 28 institutions in the years 2006-2009. The study previously reported that Bevacizumab was safe and well-tolerated in combination with cisplatin and radiation therapy in this population. Now the group reports on the secondary efficacy endpoints at a median follow-up time of 3.8 years.

Specifically the group evaluated the addition of 10mg/kg bevacizumab every two weeks for 3 cycles during
'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. ALS patients differ on treatment choices in later phases of disease
2. Reach2HD, a Phase II study in Huntingtons disease, launched
3. Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
4. Phase III trial of dapivirine ring begins in Africa: New HIV prevention approach for women
5. IDRI and Medicago announce authorization to initiate a Phase 1 clinical trial for an H5N1 vaccine
6. COPD Foundation and BWH announces second phase of groundbreaking COPDGene project
7. JDRF announces winners of first phase of Agnes Varis Glucose-Responsive Insulin Challenge
8. Positive results from Phase 1/2 stem cell trial reported
9. New monoclonal antibody inhibits tumor growth in advanced solid tumors in phase I clinical trial
10. Teva to present new Phase III data for QNASL® Nasal Aerosol at the 2012 ACAAI Meeting
11. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer 'promising'
(Date:8/22/2014)... LA The LSU Health New Orleans School ... Nursing Traineeship grant to increase access to advanced ... and under-represented groups, as well as veterans. The ... Department of Health and Human Services awarded the ... as the grant,s project director., The Advanced Education ...
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 Natural ... Kevin Richardson to restore his own vision from legally blind ... Michaels, prompting an investigative review. , “There is a ... or contacts for everyday function, and most people just think ... to corrective eye surgery that can be pretty risky at ...
(Date:8/22/2014)... oncogenic somatic mutation at amino acid 918 in the ... small cell lung cancer (SCLC) tumors and enforced expression ... intracellular signaling and cell growth. , SCLC is a ... all lung cancers and is strongly associated with tobacco ... extensively examined for genomic alterations and targeted therapies are ...
(Date:8/22/2014)... Vegas, NV (PRWEB) August 22, 2014 ... by Dr. Sen and Dr. Samantha Pearson to help ... contacts, and avoid corrective vision surgery by instead improving ... Michaels, prompting an investigative review. , “There’s a ... of dollars in revenue each year—it’s because people just ...
(Date:8/22/2014)... Prairie du Sac, Wisconsin (PRWEB) August 22, 2014 ... FasciaDerm® PFTape™ System for Plantar Fasciitis, an exciting new ... The product allows you to stay active while you ... per application. This is truly a new technology – ... patented and affordable. , FasciaDerm® PFTape™ System for ...
Breaking Medicine News(10 mins):Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2
... 28 WellSpring Pharmaceutical,Corporation, a growing North American-based ... named Chief Operating Officer.,Formerly, Ms. Shusko held the ... in early 2000. In her new role as ... her areas of oversight,to operations with an initial ...
... NQF-endorsed measures can improve quality of care for ... the,importance of quality healthcare for mothers and newborns ... measure and thereby,improve care received by mothers and ... discharge. Consensus standards improve quality,of care by standardizing ...
... who received blood that was 29 days or older faced ... Hospital patients who receive a transfusion of stored blood that ... developing one or more serious infections compared to those who ... pointed out that current U.S. regulations set the upper limit ...
... Device Designed to Minimize Discomfort and Pain Following ... a world-leading,manufacturer of ostomy and wound care products, ... a new post-operative ostomy,device. The product offers clinicians ... manage abdominal pain in the days and weeks ...
... Today, PARI Respiratory,Equipment presented a comparative study ... in-vitro performance and delivery,efficiency of budesonide inhalation ... study show that the LC Sprint,Reusable Nebulizer ... average,of 4.9 minutes, and had the highest ...
... of Portland,Oregon is pleased to announce its partnership ... a new company, Wellsource Health Solutions.,This joint venture ... provide,full-service solutions that meet the specific needs of ... Customers and their,participants will benefit from a new ...
Cached Medicine News:Health News:WellSpring Pharmaceutical Corp. Names Wendy Shusko as New Chief Operating Officer 2Health News:National Quality Forum Endorses National Consensus Standards for Perinatal Care 2Health News:National Quality Forum Endorses National Consensus Standards for Perinatal Care 3Health News:Older Blood Boosts Chances of Infection in Transfusion Patients 2Health News:Older Blood Boosts Chances of Infection in Transfusion Patients 3Health News:ConvaTec Launches SUR-FIT Natura(R) Low-Pressure Adaptor 2Health News:ConvaTec Launches SUR-FIT Natura(R) Low-Pressure Adaptor 3Health News:PARI Respiratory Releases Results of Study Comparing Nebulizers Delivering Budesonide at CHEST 2008 2Health News:Wellsource Partners With Health Solutions Ltd. to Form Best-in-Class Health and Wellness Solutions for Its Clients. 2Health News:Wellsource Partners With Health Solutions Ltd. to Form Best-in-Class Health and Wellness Solutions for Its Clients. 3
(Date:8/22/2014)... , Aug. 22, 2014 /PRNewswire/ - SQI ... that develops and commercializes proprietary technologies and products ... has entered into a Master Service Agreement to ... DNA-based pathogen detection assays. During the initial phase ... deliver an automated working prototype of one of ...
(Date:8/21/2014)... , Aug. 21, 2014 Nektar ... International Inc. today announced positive results from its ... an investigational, extended half-life recombinant factor VIII (rFVIII) ... Factor (Recombinant)], which met its primary endpoint in ... arm compared to the on-demand arm. ...
(Date:8/21/2014)... Canadian Epilepsy Alliance (CEA) is thrilled to announce the launch ... the most common neurological disorder in Canada ... tells a fictional story based on the experiences of 14-year-old ... "Despite the fact that epilepsy affects 1 ... lack of awareness out there," says Gail Dempsey , ...
Breaking Medicine Technology:SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3
This is an antigen-capture assay intended for the detection of histidine-rich protein ll (PfHRP-ll), which is released from Malaria-infected red blood cells....
Core Malaria Pf is a rapid self performing, qualitative, two site sandwich immunoassay for the determination of P. falciparum specific histidine rich protein 2 (Pf HRP-2) in whole blood samples...
Ultraview 1700 Central Monitor...
The Hypervisor VI is a solution for telemetry, LAN and wireless LAN networking. It includes bi-directional communication with Mindray bedside patient monitors and can store waveforms and numeric info...
Medicine Products: